Application of mass cytometry to characterize hematopoietic stem cells in apheresis products of patients with hematological malignancies
Introduction: Hematopoietic stem cell transplantation (HSCT) is a widely used therapy, but its success largely depends on the number and quality of stem cells collected. Current evidence shows the complexity of the hematopoietic system, which implies that, in the quality assurance of the apheresis p...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137923026007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850053492014579712 |
|---|---|
| author | Carlos Agustin Villegas-Valverde Antonio Alfonso Bencomo-Hernandez Yandy M. Castillo-Aleman Yendry Ventura-Carmenate Imilla Casado-Hernandez Rene Antonio Rivero-Jimenez |
| author_facet | Carlos Agustin Villegas-Valverde Antonio Alfonso Bencomo-Hernandez Yandy M. Castillo-Aleman Yendry Ventura-Carmenate Imilla Casado-Hernandez Rene Antonio Rivero-Jimenez |
| author_sort | Carlos Agustin Villegas-Valverde |
| collection | DOAJ |
| description | Introduction: Hematopoietic stem cell transplantation (HSCT) is a widely used therapy, but its success largely depends on the number and quality of stem cells collected. Current evidence shows the complexity of the hematopoietic system, which implies that, in the quality assurance of the apheresis product, the hematopoietic stem cells are adequately characterized and quantified, in which mass cytometry (MC) can provide its advantages in high-dimensional analysis. Objective: This research aimed to characterize and enumerate CD45dim/CD34+ stem cells using the MC in apheresis product yields from patients with chronic lymphoid malignant diseases undergoing autologous transplantation at the Abu Dhabi Stem Cells Center. Methods: An analytical and cross-sectional study was performed on 31 apheresis products from 15 patients diagnosed with multiple myeloma (n = 9) and non-Hodgkin lymphomas (n = 6) eligible for HSCT. The MC was employed using the MaxPar Kit for stem cell immunophenotyping. The analysis was performed manually in the Kaluza and unsupervised by machine learning in Cytobank Premium. Results: An excellent agreement was found between mass and flow cytometry for the relative and absolute counts of CD45dim/CD34+ cells (Bland-Altman bias: -0.029 and -64, respectively), seven subpopulations were phenotyped and no lineage bias was detected for any of the methods used in the pool of collected cells. A CD34+/CD38+/CD138+ population was seen in the analyses performed on four patients with multiple myeloma. Conclusions: The MC helps to characterize subpopulations of stem cells in apheresis products. It also allows cell quantification by double platform. Unsupervised analysis allows results completion and validation of the manual strategy. The proposed methodology can be extended to apheresis products for purposes other than HSCT. |
| format | Article |
| id | doaj-art-7c9053ca06e040ba9e95f30747ca1c1b |
| institution | DOAJ |
| issn | 2531-1379 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj-art-7c9053ca06e040ba9e95f30747ca1c1b2025-08-20T02:52:31ZengElsevierHematology, Transfusion and Cell Therapy2531-13792024-12-0146S59S7010.1016/j.htct.2023.10.008Application of mass cytometry to characterize hematopoietic stem cells in apheresis products of patients with hematological malignanciesCarlos Agustin Villegas-Valverde0Antonio Alfonso Bencomo-Hernandez1Yandy M. Castillo-Aleman2Yendry Ventura-Carmenate3Imilla Casado-Hernandez4Rene Antonio Rivero-Jimenez5Corresponding author at: Senior Research Scientist, Specialist in Immunology. Associate Professor of Immunology, Abu Dhabi Stem Cells Center (ADSCC), Address: Villa 25, Al Misahah Street, Rowdhat, PO Box 4600, Zone 1, Abu Dhabi, United Arab Emirates Website: http://www.adscc.ae/.; Abu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, United Arab EmiratesAbu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, United Arab EmiratesAbu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, United Arab EmiratesAbu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, United Arab EmiratesAbu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, United Arab EmiratesAbu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, United Arab EmiratesIntroduction: Hematopoietic stem cell transplantation (HSCT) is a widely used therapy, but its success largely depends on the number and quality of stem cells collected. Current evidence shows the complexity of the hematopoietic system, which implies that, in the quality assurance of the apheresis product, the hematopoietic stem cells are adequately characterized and quantified, in which mass cytometry (MC) can provide its advantages in high-dimensional analysis. Objective: This research aimed to characterize and enumerate CD45dim/CD34+ stem cells using the MC in apheresis product yields from patients with chronic lymphoid malignant diseases undergoing autologous transplantation at the Abu Dhabi Stem Cells Center. Methods: An analytical and cross-sectional study was performed on 31 apheresis products from 15 patients diagnosed with multiple myeloma (n = 9) and non-Hodgkin lymphomas (n = 6) eligible for HSCT. The MC was employed using the MaxPar Kit for stem cell immunophenotyping. The analysis was performed manually in the Kaluza and unsupervised by machine learning in Cytobank Premium. Results: An excellent agreement was found between mass and flow cytometry for the relative and absolute counts of CD45dim/CD34+ cells (Bland-Altman bias: -0.029 and -64, respectively), seven subpopulations were phenotyped and no lineage bias was detected for any of the methods used in the pool of collected cells. A CD34+/CD38+/CD138+ population was seen in the analyses performed on four patients with multiple myeloma. Conclusions: The MC helps to characterize subpopulations of stem cells in apheresis products. It also allows cell quantification by double platform. Unsupervised analysis allows results completion and validation of the manual strategy. The proposed methodology can be extended to apheresis products for purposes other than HSCT.http://www.sciencedirect.com/science/article/pii/S2531137923026007Autologous hematopoietic stem cell transplant (AHSCT)Flow and mass cytometryImmunophenotypingApheresisHematological malignancies |
| spellingShingle | Carlos Agustin Villegas-Valverde Antonio Alfonso Bencomo-Hernandez Yandy M. Castillo-Aleman Yendry Ventura-Carmenate Imilla Casado-Hernandez Rene Antonio Rivero-Jimenez Application of mass cytometry to characterize hematopoietic stem cells in apheresis products of patients with hematological malignancies Hematology, Transfusion and Cell Therapy Autologous hematopoietic stem cell transplant (AHSCT) Flow and mass cytometry Immunophenotyping Apheresis Hematological malignancies |
| title | Application of mass cytometry to characterize hematopoietic stem cells in apheresis products of patients with hematological malignancies |
| title_full | Application of mass cytometry to characterize hematopoietic stem cells in apheresis products of patients with hematological malignancies |
| title_fullStr | Application of mass cytometry to characterize hematopoietic stem cells in apheresis products of patients with hematological malignancies |
| title_full_unstemmed | Application of mass cytometry to characterize hematopoietic stem cells in apheresis products of patients with hematological malignancies |
| title_short | Application of mass cytometry to characterize hematopoietic stem cells in apheresis products of patients with hematological malignancies |
| title_sort | application of mass cytometry to characterize hematopoietic stem cells in apheresis products of patients with hematological malignancies |
| topic | Autologous hematopoietic stem cell transplant (AHSCT) Flow and mass cytometry Immunophenotyping Apheresis Hematological malignancies |
| url | http://www.sciencedirect.com/science/article/pii/S2531137923026007 |
| work_keys_str_mv | AT carlosagustinvillegasvalverde applicationofmasscytometrytocharacterizehematopoieticstemcellsinapheresisproductsofpatientswithhematologicalmalignancies AT antonioalfonsobencomohernandez applicationofmasscytometrytocharacterizehematopoieticstemcellsinapheresisproductsofpatientswithhematologicalmalignancies AT yandymcastilloaleman applicationofmasscytometrytocharacterizehematopoieticstemcellsinapheresisproductsofpatientswithhematologicalmalignancies AT yendryventuracarmenate applicationofmasscytometrytocharacterizehematopoieticstemcellsinapheresisproductsofpatientswithhematologicalmalignancies AT imillacasadohernandez applicationofmasscytometrytocharacterizehematopoieticstemcellsinapheresisproductsofpatientswithhematologicalmalignancies AT reneantonioriverojimenez applicationofmasscytometrytocharacterizehematopoieticstemcellsinapheresisproductsofpatientswithhematologicalmalignancies |